Genentech, a member of the Roche (RHHBY), presented results from thePhase III SUNMO study showing Lunsumio administered subcutaneously in combination with Polivy demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival and objective response rate compared to Rituxan, gemcitabine and oxaliplatin, in people with relapsed or refractory large B-cell lymphoma who are not eligible for transplant. At a median follow-up of 23.2 months, the Lunsumio and Polivy combination demonstrated a 59% reduction in risk of disease progression or death compared to R-GemOx. Median progression free survival was three times longer with Lunsumio and Polivy at 11.5 months, compared to 3.8 months for R-GemOx, and 12-month PFS was more than doubled at 48.5% versus 17.8%, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Sarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall Street
- MAIA Biotechnology, Roche sign supply agreement for cancer therapies
- Trump administration weighs crackdown on pharma ads, Bloomberg says
- Roche, AbbVie say Phase III VERONA study faliled in MDS
- Roche, AbbVie says Phase III VERONA study faliled in MDS